LIFEVANTAGE CORP (LFVN) Current Ratio
- Current ratio · latest quarter: Value 1.89×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.89× | Current assets / current liabilities. $38.30M ÷ $20.23M ≈ 1.89× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 38.30M USD | Assets, Current |
| Current obligations | 20.23M USD | Liabilities, Current |
| Cash and equivalents | (m) | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Debt Securities, Available-for-sale, Current |
| Customer receivables | 2.99M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 16.17M USD | Inventory, Net |
| Payables | 5.16M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $38.30M | $20.23M | (m) | (m) | $2.99M | $16.17M | $5.16M | (m) | 1.89× |
| 2026-03-31 | $39.31M | $20.10M | (m) | (m) | $2.42M | $18.38M | $5.15M | (m) | 1.96× |
| 2025-12-31 | $38.56M | $19.01M | (m) | (m) | $2.26M | $18.98M | $4.89M | (m) | 2.03× |
| 2025-09-30 | $45.05M | $18.83M | (m) | (m) | $2.42M | $20.59M | $4.36M | (m) | 2.39× |
| 2025-06-30 | $50.89M | $27.22M | (m) | (m) | $3.29M | $20.67M | $4.60M | (m) | 1.87× |
| 2025-03-31 | $54.11M | $32.58M | (m) | (m) | $3.24M | $22.22M | $7.04M | (m) | 1.66× |
| 2024-12-31 | $45.79M | $27.55M | (m) | (m) | $2.09M | $17.47M | $5.76M | (m) | 1.66× |
| 2024-09-30 | $38.81M | $22.07M | (m) | (m) | $2.97M | $16.91M | $5.27M | (m) | 1.76× |
| 2024-06-30 | $37.65M | $22.31M | $16.89M | (m) | $2.95M | $15.05M | $5.85M | (m) | 1.69× |
| 2024-03-31 | $37.80M | $22.48M | (m) | (m) | $2.13M | $15.16M | $6.95M | (m) | 1.68× |
| 2023-12-31 | $38.66M | $23.02M | (m) | (m) | $2.33M | $14.97M | $6.24M | (m) | 1.68× |
| 2023-09-30 | $41.90M | $24.70M | (m) | (m) | $2.50M | $15.71M | $6.76M | (m) | 1.70× |
| 2023-06-30 | $44.28M | $19.61M | $21.61M | (m) | $1.61M | $16.07M | $3.50M | (m) | 2.26× |
| 2023-03-31 | $44.34M | $21.40M | (m) | (m) | $2.35M | $18.45M | $5.82M | (m) | 2.07× |
| 2022-12-31 | $44.36M | $23.33M | (m) | (m) | $2.41M | $20.43M | $8.23M | (m) | 1.90× |
| 2022-09-30 | $42.92M | $22.77M | (m) | (m) | $1.92M | $18.64M | $7.85M | (m) | 1.89× |
| 2022-06-30 | $46.96M | $25.73M | $20.19M | (m) | $3.34M | $16.47M | $7.46M | (m) | 1.83× |
| 2022-03-31 | $45.06M | $23.61M | (m) | (m) | $2.80M | $16.28M | $6.53M | (m) | 1.91× |
| 2021-12-31 | $42.79M | $22.17M | (m) | (m) | $2.42M | $15.43M | $4.87M | (m) | 1.93× |
| 2021-09-30 | $44.90M | $22.27M | (m) | (m) | $3.25M | $16.08M | $4.84M | (m) | 2.02× |
| 2021-06-30 | $48.05M | $25.20M | $23.17M | (m) | $2.92M | $16.14M | $6.74M | (m) | 1.91× |
| 2021-03-31 | $43.62M | $22.28M | (m) | (m) | $3.31M | $14.82M | $5.16M | (m) | 1.96× |
| 2020-12-31 | $42.46M | $22.45M | (m) | (m) | $3.27M | $14.71M | $5.16M | (m) | 1.89× |
| 2020-09-30 | $41.03M | $22.02M | (m) | (m) | $2.34M | $14.80M | $4.73M | (m) | 1.86× |
| 2020-06-30 | $43.87M | $25.02M | $22.14M | (m) | $2.61M | $13.89M | $3.52M | (m) | 1.75× |
| 2020-03-31 | $37.84M | $23.32M | (m) | (m) | $1.16M | $14.74M | $4.00M | $0.00 | 1.62× |
| 2019-12-31 | $37.61M | $25.25M | (m) | (m) | $1.79M | $14.22M | $3.90M | $484.00K | 1.49× |
| 2019-09-30 | $42.36M | $25.31M | (m) | (m) | $2.12M | $14.78M | $5.15M | $969.00K | 1.67× |
| 2019-06-30 | $43.19M | $26.20M | $18.82M | (m) | $2.07M | $13.75M | $5.18M | $1.45M | 1.65× |
| 2019-03-31 | $42.68M | $27.48M | (m) | (m) | $1.92M | $14.49M | $5.07M | $1.94M | 1.55× |
| 2018-12-31 | $43.66M | $28.76M | $18.99M | (m) | $2.38M | $13.30M | $4.11M | $2.00M | 1.52× |
| 2018-09-30 | $40.53M | $23.59M | $17.12M | (m) | $2.37M | $13.28M | $3.93M | $2.00M | 1.72× |
| 2018-06-30 | $38.94M | $23.80M | $16.65M | (m) | $2.07M | $13.63M | $3.81M | $2.00M | 1.64× |
| 2018-03-31 | $39.23M | $25.69M | $13.95M | (m) | $1.33M | $15.82M | $4.63M | $2.00M | 1.53× |
| 2017-12-31 | $35.29M | $22.73M | $12.79M | (m) | $1.54M | $16.82M | $3.27M | $2.00M | 1.55× |
| 2017-09-30 | $34.03M | $22.13M | $12.29M | (m) | $1.66M | $15.36M | $3.15M | $2.00M | 1.54× |
| 2017-06-30 | $35.55M | $23.36M | $11.46M | (m) | $1.33M | $16.57M | $4.85M | $2.00M | 1.52× |
| 2017-03-31 | $37.85M | $24.91M | $9.20M | (m) | $1.15M | $19.14M | $6.49M | $2.00M | 1.52× |
| 2016-12-31 | $36.72M | $23.54M | $11.73M | (m) | $717.00K | $21.38M | $5.04M | $2.00M | 1.56× |
| 2016-09-30 | $39.57M | $26.71M | $10.22M | (m) | $1.43M | $23.92M | $7.73M | $2.00M | 1.48× |
| 2016-06-30 | $43.11M | $30.63M | $7.88M | (m) | $1.55M | $25.12M | $8.89M | $2.00M | 1.41× |
| 2016-03-31 | $35.70M | $25.30M | $8.49M | (m) | $2.04M | $17.00M | $5.94M | $2.00M | 1.41× |
| 2015-12-31 | $36.48M | $34.82M | $15.82M | (m) | $1.74M | $10.62M | $5.86M | $12.23M | 1.05× |
| 2015-09-30 | $30.86M | $27.95M | $13.69M | (m) | $1.14M | $8.54M | $2.50M | $11.72M | 1.10× |
| 2015-06-30 | $30.48M | $25.86M | $13.90M | (m) | $1.03M | $9.25M | $2.61M | $11.14M | 1.18× |
| 2015-03-31 | $34.86M | $24.80M | $15.35M | (m) | $1.26M | $10.90M | $2.72M | $9.20M | 1.41× |
| 2014-12-31 | $38.62M | $21.56M | $18.65M | (m) | $1.11M | $12.10M | $4.00M | $4.70M | 1.79× |
| 2014-09-30 | $43.79M | $23.37M | $22.14M | (m) | $1.66M | $11.01M | $4.22M | $4.70M | 1.87× |
| 2014-06-30 | $39.97M | $22.70M | $20.39M | (m) | $1.32M | $8.83M | $2.85M | $4.70M | 1.76× |
| 2014-03-31 | $56.26M | $25.30M | $35.68M | (m) | $2.61M | $8.58M | $2.64M | (m) | 2.22× |
| 2013-12-31 | $52.87M | $21.92M | $34.45M | (m) | $873.00K | $9.84M | $2.81M | (m) | 2.41× |
| 2013-09-30 | $44.89M | $18.43M | $27.96M | (m) | $923.00K | $10.63M | $3.00M | (m) | 2.44× |
| 2013-06-30 | $45.94M | $20.57M | $26.30M | (m) | $1.79M | $10.52M | $5.17M | $0.00 | 2.23× |
| 2013-03-31 | $43.87M | $18.58M | $27.24M | (m) | $1.38M | $8.03M | $4.61M | (m) | 2.36× |
| 2012-12-31 | $44.34M | $18.74M | $28.47M | (m) | $728.00K | $9.55M | $4.78M | (m) | 2.37× |
| 2012-09-30 | $41.75M | $15.50M | $25.18M | (m) | $230.00K | $13.07M | $2.42M | (m) | 2.69× |
| 2012-06-30 | $38.83M | $16.03M | $24.65M | (m) | $333.00K | $11.35M | $3.62M | (m) | 2.42× |
| 2012-03-31 | $28.88M | $10.77M | $16.90M | $0.00 | $817.16K | $6.98M | $0.00 | (m) | 2.68× |
| 2011-12-31 | $20.88M | $15.30M | $13.46M | $0.00 | $759.10K | $3.03M | $1.68M | (m) | 1.36× |
| 2011-09-30 | $14.52M | $14.01M | $9.44M | $350.00K | $1.32M | $2.76M | $1.21M | (m) | 1.04× |
| 2011-06-30 | $10.28M | $13.38M | $6.37M | $350.00K | $941.80K | $2.12M | $799.21K | (m) | 0.77× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |